本文源自：金融界AI电报 周二，美国科技股七巨头指数涨0.36%，报195.68点。成分股英伟达收涨1.16%，Meta涨1.03%，亚马 逊、苹果、谷歌A、特斯拉至多涨0.39%，微软则收跌0.89%。此外，AMD收涨0.27%，台积电则收跌 0.46%，伯克希尔哈撒韦B类股跌0.62%，礼来跌0.70%。"超大"市值科技股指数跌0.07%，报372.20点。 除了特斯拉、谷歌A、AMD、苹果、微软、英伟达、Meta Platforms、亚马逊之外，博通收跌0.92%，奈 飞跌1.40%，甲骨文跌1.43%，Salesforce跌1.95%，高通跌2.11%，Adobe跌2.59%。 ...

周二（3月10日），美国科技股七巨头（Magnificent 7）指数涨0.36%，报195.68点。成分股英伟达收涨 1.16%，Meta涨1.03%，亚马逊、苹果、谷歌A、特斯拉至多涨0.39%，微软则收跌0.89%。此外，AMD 收涨0.27%，台积电则收跌0.46%，伯克希尔哈撒韦B类股跌0.62%，礼来跌0.70%。"超大"市值科技股指 数跌0.07%，报372.20点。除了特斯拉、谷歌A、AMD、苹果、微软、英伟达、Meta Platforms、亚马逊 之外，博通收跌0.92%，奈飞跌1.40%，甲骨文跌1.43%，Salesforce跌1.95%，高通跌2.11%，Adobe跌 2.59%。 来源：滚动播报 ...

Core Insights - Eli Lilly and Company (NYSE: LLY) is recognized for its innovative drug development and healthcare solutions, with Bernstein reiterating an "Outperform" rating, indicating confidence in the company's future performance and growth potential [1][6] Investment Activity - The Bank of Montreal Can increased its stake in Eli Lilly by 8.9% during the third quarter, now holding 1,569,917 shares valued at $1.2 billion, which is approximately 0.17% of Eli Lilly's total shares [2][6] - Brighton Jones LLC raised its holdings in Eli Lilly by 22% in the fourth quarter, now owning 9,597 shares valued at $7.4 million, while Revolve Wealth Partners LLC increased its holdings by 2.8%, now possessing 1,471 shares, reflecting a broader trend of investor confidence [3] Stock Performance - Eli Lilly's stock is currently priced at $1,008.39, reflecting an increase of 1.82% or $18.06, with fluctuations between a low of $980.58 and a high of $1,008.86 during the day [4] - Over the past year, Eli Lilly's stock has reached a high of $1,133.95 and a low of $623.78, indicating volatility and potential for growth [4] - The company's market capitalization is approximately $951.27 billion, showcasing its significant presence in the pharmaceutical sector, with a trading volume of 2,016,365 shares on the NYSE [5][6]

Eli Lilly and Company (NYSE:LLY) is one of the top stocks that will make you rich in 10 years. Eli Lilly and Company (LLY) Set to Launch Oral Obesity Drug in Q2, Reuters Reports Reuters reported on March 2 that Eli Lilly and Company (NYSE:LLY) CFO ‌Lucas Montarce stated that the company is making preparations to launch its new oral obesity drug, orforglipron, in the United ​States as early as the second quarter of ​this year once it gets approval from the ⁠Food and Drug Administration. The company furt ...

记者丨韩利明 编辑丨季媛媛 骆一帆 随着跨国药企陆续披露2025年业绩报告，全球制药行业的新一轮竞争格局逐步清晰。 业绩榜单中，强生以全球941.93亿美元的总营收斩获榜首，旗下创新制药和医疗科技两大核心 业务板块分别收入604.01亿美元（+6%）和337.92亿美元（+6.1%）；礼来凭借44%的高增 速，实现651.79亿美元的全年营收，成为增速最快的头部药企。此外，赛诺菲、诺华、阿斯利 康、艾伯维等头部企业营收均保持上升趋势，共同支撑全球制药行业稳步发展。 | | | | | 2025年营收前十跨国药企财务数据(单位:亿美元) | | | | --- | --- | --- | --- | --- | --- | --- | | 排名 | 公司 | 全球总营收 | 同比增速 | 中国区营收 | 同比增速 | 备注 | | 1 | 强生 | 941.93 | 6% | | | | | 2 | 罗氏 | 744. 28 | 7% | 36. 71 | 10% | 全球营收615. 16亿瑞士法郎:中国 区制药业务营收30.34亿瑞士法 郎,按1瑞士法郎=1. 2099美元换算 | | 3 | 礼来 | 6 ...

Core Insights - Eli Lilly and Company (LLY) has launched its Employer Connect platform to address the access gap in U.S. obesity care, providing flexible solutions for employers and employees [1][2] Group 1: Employer Connect Platform - The Employer Connect platform aims to enhance employee access to obesity management medicines by facilitating coordination between employers and independent program administrators [1] - The platform offers various cost-sharing solutions to reduce out-of-pocket expenses for employees undergoing treatment for obesity [2] Group 2: Market Context - Eli Lilly develops and sells pharmaceutical products across multiple therapeutic areas, including oncology, diabetes, immunology, and neuroscience [3]

Eli Lilly said on Monday a small number of basic Medicare drug plans may not follow the $50 per month cap on out-of-pocket costs for its weight-loss drugs, under the Medicare agency's weight-loss drug coverage model. ...

Core Insights - Novo Nordisk (NVO) shares have dropped 22% in the past month, resulting in a loss of nearly $50 billion in market capitalization due to disappointing clinical developments and rising pricing pressures [2] - Eli Lilly (LLY) has emerged as a significant competitor in the GLP-1 obesity market, with its therapy Zepbound (tirzepatide) outperforming NVO's Wegovy in clinical trials [3][4] - Novo Nordisk plans to cut U.S. list prices for Wegovy, Ozempic, and Rybelsus to $675 per month starting January 2027 to enhance patient access, which may compress margins amid increasing competition [7] Competitive Landscape - Eli Lilly's Zepbound achieved 25.5% weight loss in a phase III study, surpassing Novo Nordisk's CagriSema, which recorded 23% weight loss, marking a competitive setback for NVO [4][5] - Lilly's oral GLP-1 candidate, orforglipron, has also outperformed Novo Nordisk's Rybelsus in a phase III study for type II diabetes, further strengthening Lilly's position in the market [6] Financial Performance - Novo Nordisk's stock has underperformed, losing 29.1% over the past six months compared to the industry's 20% growth [19] - The company's shares currently trade at a price/earnings ratio of 11.59, significantly lower than the industry average of 17.90, indicating a discount in valuation [22] Growth Outlook - Novo Nordisk's growth outlook is deteriorating due to slowing demand, rising costs, and limited near-term catalysts, with earnings estimates for 2026 and 2027 declining [8][24] - The company is expanding its portfolio beyond GLP-1 treatments, seeking approvals for therapies in rare diseases and liver care, including treatments for hemophilia and metabolic dysfunction-associated liver disease [15][16] Pipeline Developments - Novo Nordisk is advancing several next-generation obesity candidates, including CagriSema and amycretin, to strengthen its competitive position in the obesity market [17][18] - The company has also entered partnerships to develop oral small-molecule medicines for obesity and diabetes, indicating a strategic focus on expanding its treatment options [18]

医药生物 证券研究报告 行业投资策略周报 / 2026.03.09 投资评级:看好(维持) 最近 12 月市场表现 -9% -2% 5% 12% 19% 25% 医药生物 沪深300 上证指数 分析师 华挺 SAC 证书编号：S0160523010002 huating@ctsec.com 联系人 宋田田 songtt@ctsec.com 相关报告 1. 《原料药板块有望周期性回升》 2026- 02-02 2. 《关注产业趋势给原料药企业带来的新机 遇》 2026-01-19 礼来口服 GLP-1 小分子 Orforglipron 获批在即 3. 《小核酸药物龙头招股启动，赛道或成全 年度医药主线》 2026-01-05 Orforglipron 获批在即，关注产业链机遇 核心观点 请阅读最后一页的重要声明！ ❖ 礼来 orforglipron III 期临床试验结果表现优异：礼来公布了 ACHIEVE- 3 研究的详细结果，在主要终点及所有关键次要终点上均优于口服司美格鲁 肽。2026 年 2 月 26 日，礼来公布了 ACHIEVE-3 研究的详细结果，ACHIEVE- 3 是该研究系列的首个头对头对照 ...

借助替而泊肽的高增长，礼来 26 年仍将增长迅速 ➢ 25 年 Q4 收入+42.6%至 192.9 亿美元：公司 25 年 Q4 收入同比 +42.6%至 192.9 亿美元，其中总销量增 46%，但部分收入被售价下降 5%所抵消，收入增长主要由替而泊肽增长驱动。毛利率同比+0.3 个百 分点至 82.5%，公司 GAAP 净利润同比+50.5%至 66.4 亿美元，EPS 同比 +51.4%至 7.39 美元，Q4 公司分红+回购 28 亿美元。26 年虽然价格压 力加剧（预计-10%-15%），且部分成熟产品如 Trulicity、Taltz、 Verzenio 等销售预计持平或下滑，但借助替而泊肽和其他新兴药物的 增长，公司仍预计 26 年的营收增长 23%-27%至 800-830 亿美元， EPS+46%-53%至 33.5-35.0 美元。 ➢ 各版块表现情况：1、代谢板块：25 年 Q4 收入同比增长 59.1%至 144.9 亿美元，占公司总收入的 75%，其中替而泊肽收入同比增长 115%至 116.7 亿美元，其中降糖版 Mounjaro 收入同比+110%至 74.1 亿美元，美国总处 ...